Key Highlights:
- Sarepta Therapeutics (SRPT, Financial) and Roche are working to resume trials with Elevidys after a temporary hold.
- Analysts have set an average price target of $166.73 for SRPT, suggesting significant upside potential.
- GuruFocus projects a remarkable 282.33% upside based on the estimated GF Value.
Sarepta Therapeutics (SRPT), in collaboration with Roche, is diligently pursuing efforts to lift a clinical hold on Elevidys trials. This action follows a patient death, and both entities are preparing to present compelling data to European regulators. Importantly, an independent committee has reinforced the drug's favorable risk-benefit profile, greenlighting the continuation of the trials.
Optimistic Wall Street Projections
Wall Street displays a positive outlook for Sarepta Therapeutics Inc (SRPT, Financial), with 22 analysts setting a one-year average price target of $166.73. This target indicates a substantial upside of 189.77% considering the current trading price of $57.54. Price targets range from a high of $215.00 to a low of $70.00. For more information, visit the Sarepta Therapeutics Inc (SRPT) Forecast page.
Furthermore, the consensus from 24 brokerage firms reflects an encouraging "Outperform" rating, with an average recommendation score of 1.9. This rating employs a scale from 1 to 5, where 1 represents Strong Buy and 5 indicates Sell.
Insight from GuruFocus
According to GuruFocus' estimates, the projected GF Value for Sarepta Therapeutics Inc (SRPT, Financial) in one year is $219.99. This projection suggests a remarkable upside of 282.33% from the current market price of $57.54. The GF Value calculation considers historical trading multiples, past business growth, and anticipated future performance. For a deeper dive, visit the Sarepta Therapeutics Inc (SRPT) Summary page.
